Key Takeaways
- On November 26, 2025, Bloomberg reported that US Medicare may soon cover cannabidiol (CBD) treatments for certain patients, especially seniors in oncology and palliative care.
- Cannabis stocks, led by Tilray’s 3.7% gain, rose significantly following the news, with Curaleaf, Innovative Industrial Properties, Aurora Cannabis, Cronos Group, and Canopy Growth also posting increases.
- The initiative reflects growing federal momentum toward legitimizing CBD’s medical use under Medicare, potentially opening new revenue sources for the cannabis industry.
On November 26, 2025, cannabis stocks climbed after Bloomberg disclosed that the US Medicare program is contemplating coverage of cannabidiol (CBD) treatments for select patients. The report specifies that this move would primarily benefit seniors undergoing cancer treatment or receiving palliative care. This potential policy adjustment has energized the cannabis sector by signaling increased federal support and new medical markets for CBD products.
Medicare’s Possible CBD Coverage Spurs Cannabis Stock Rally
According to insiders, the Centers for Medicare & Medicaid Services (CMS) is drafting a plan that could grant Medicare beneficiaries access to CBD therapies. The early focus is on senior patients experiencing cancer-related symptoms and those in palliative care environments. CBD, a cannabis-derived compound without psychoactive effects, is commonly used for alleviating pain, inflammation, anxiety, and sleep disturbances.
Following the Bloomberg report, cannabis equities saw notable gains. Tilray Inc (NASDAQ: TLRY) led the upward momentum with a 3.7% increase. Curaleaf Holdings Inc (OTC: CURLF) advanced 2.2%, while Innovative Industrial Properties Inc (NYSE: IIPR) rose 2.4%. Additional sector participants like Aurora Cannabis Inc (NASDAQ: ACB), Cronos Group Inc (NASDAQ: CRON), and Canopy Growth Corp (NASDAQ: CGC) also moved higher, gaining 1.5%, 1.4%, and 0.7% respectively. These price movements underscore investor optimism around expanded Medicare-backed cannabis therapies.
Policy Drivers and Industry Impacts
The Bloomberg investigation further revealed that Howard Kessler, a payments industry financier promoting broader CBD access, met recently with Health and Human Services Secretary Robert F. Kennedy Jr. to advance the discussion. CMS officials declined to comment on the emerging initiative, leaving the plan unofficial but highlighting increased regulatory interest.
Trump’s Tariffs May Spark an AI Gold Rush
One tiny tech stock could ride this $1.5 trillion wave — before the tariff pause ends.
This development builds on earlier market enthusiasm from September, when former President Donald Trump publicly endorsed Medicare coverage of CBD via a video on Truth Social, calling the compound a natural remedy with potential life-extending benefits for seniors.
If Medicare officially incorporates CBD coverage for oncology and palliative care patients, it would mark a significant federal endorsement, enhancing treatment accessibility for vulnerable seniors. For cannabis companies, this could unlock substantial new revenue opportunities tied to legitimate medical cannabis products supported by insurance.
Cannabis: Market Outlook
With Medicare reportedly near approving CBD coverage targeted at senior patients in critical care, cannabis companies like Tilray, Curaleaf, and Innovative Industrial Properties have already experienced immediate stock price gains. Investors appear to anticipate a broader policy embrace that could drive longer-term revenue growth and sector expansion. As CMS’s plans develop, the cannabis industry stands poised at a crucial inflection point, reflecting increasing integration of CBD medical use into federally insured healthcare.
